![Erik Bergman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Erik Bergman formerly worked at Kibion AB, as Acting Chief Executive Officer, Senzime AB, as Chief Financial Officer & Executive Vice President from 2019 to 2022, Novavax AB, as Chief Financial Officer from 2010 to 2013, and Orexo AB, as Chief Financial Officer.
Ehemalige bekannte Positionen von Erik Bergman
| Unternehmen | Position | Ende |
|---|---|---|
| SENZIME AB | Finanzdirektor/CFO | 01.01.2022 |
Kibion AB
 Kibion AB Medical SpecialtiesHealth Technology Provides solutions for rapid urea breath tests for diagnosing the stomach ulcer | Präsident | 15.11.2010 |
Novavax AB
 Novavax AB Pharmaceuticals: GenericHealth Technology Develops, manufactures, and sells vaccine adjuvants | Finanzdirektor/CFO | - |
| OREXO AB | Finanzdirektor/CFO | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
7
Beziehungen ersten Grades
4
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Senzime AB
 Senzime AB Medical SpecialtiesHealth Technology Develops and markets an enzyme based biosensor technology | Health Technology |
Novavax AB
Novavax AB Pharmaceuticals: GenericHealth Technology Develops, manufactures, and sells vaccine adjuvants | Health Technology |
Orexo AB
 Orexo AB Pharmaceuticals: MajorHealth Technology Manufactures and commercializes pharmaceutical products | Health Technology |
Kibion AB
Kibion AB Medical SpecialtiesHealth Technology Provides solutions for rapid urea breath tests for diagnosing the stomach ulcer | Health Technology |
